AbbVie stock: Etentamig filing advances oncology pipeline
Published on 10/30/2026 at 11:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat AbbVie investors should watch
- Etentamig's filing expands AbbVie's late-stage oncology pipeline in multiple myeloma.
- The phase 3 CERVINO trial reported a 74.0 percent response rate and a 60 percent reduction in the risk of progression or death.
- FDA acceptance, a possible priority review and the eventual decision are the next regulatory milestones.
On Tuesday, October 27, AbbVie submitted a Biologics License Application to the U.S. Food and Drug Administration for etentamig in adults with relapsed or refractory multiple myeloma. Simply Wall St said the filing is backed by a pivotal phase 3 trial that met its primary endpoint.
Oncology pipeline gains a milestone
Etentamig is a second-generation BCMA x CD3 bispecific antibody administered on a monthly schedule. The candidate is intended for patients whose disease has returned or stopped responding after prior treatment, placing it in a heavily treated segment of multiple myeloma.
The filing adds a potential future product to AbbVie's oncology franchise, but it does not yet create marketed-product revenue. The FDA must first accept the application and complete its review before AbbVie can move etentamig into commercial use.
Trial data support the filing
The CERVINO phase 3 study enrolled 393 patients and reported a 74.0 percent response rate against 45.7 percent for standard therapies. The trial also reduced the risk of disease progression or death by 60 percent. Cytokine release syndrome occurred in about 28 percent of patients, with cases described as mild to moderate.
For investors, the filing strengthens the longer-term oncology narrative while leaving execution and regulatory timing as the main variables. AbbVie needs newer medicines to broaden its growth base as established products face competitive and lifecycle pressure. The next meaningful checkpoints are FDA acceptance, any priority review decision and the eventual approval decision.
AbbVie stock traded at 266.10 euros on Lang & Schwarz at 11:30 CEST on Friday, October 30, 3.02 percent above the Xetra close of Thursday, October 29. The real-time quote of AbbVie stock gives investors the current trading reference.
AbbVie Inc. stock at a glance
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: 4AB.DE on Xetra
- Lang & Schwarz quote: 266.10 euros at 11:30 CEST on October 30, 2026
- Change versus Xetra: 3.02 percent above the October 29 close
- Xetra close: 258.20 euros on October 29, 2026
U.S. pharmaceutical sentiment can be followed in current market reports.
Further regulatory updates and company developments are available in more news and analyses on AbbVie stock.
